Atlanta, Georgia--(Newsfile Corp. - December 2, 2021) - Holzer & Holzer, LLC is investigating whether BeyondSpring, Inc. ("BeyondSpring" or the "Company") (NASDAQ: BYSI) complied with federal securities laws. On December 1, 2021, BeyondSpring announced that it received a Complete Response Letter ("CRL") from the U.S. Food and Drug Administration ("FDA") for the Company's New Drug Application ("NDA") and that in the CRL the FDA indicated it cannot approve the Company's NDA in its current form. On this news, the Company's stock dropped.
If you purchased BeyondSpring stock and suffered a loss on that investment, you are encouraged to contact Corey D. Holzer, Esq. at email@example.com or Joshua Karr, Esq. at firstname.lastname@example.org, call our toll-free number at (888) 508-6832, or visit our website at www.holzerlaw.com to discuss your legal rights.
Holzer & Holzer, LLC is an Atlanta, Georgia law firm that dedicates its practice to vigorous representation of shareholders and investors in litigation nationwide, including shareholder class action and derivative litigation. Since its founding in 2000, Holzer & Holzer attorneys have played critical roles in recovering hundreds of millions of dollars for shareholders victimized by fraud and other corporate misconduct. More information about the firm is available through its website, www.holzerlaw.com, and upon request from the firm. Holzer & Holzer, LLC has paid for the dissemination of this promotional communication, and Corey D. Holzer is the attorney responsible for its content.
Corey D. Holzer, Esq.
(888) 508-6832 (toll-free)
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/106357